Baillie Gifford & Co. Sells 308,265 Shares of DexCom, Inc. (NASDAQ:DXCM)

Baillie Gifford & Co. trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,017,666 shares of the medical device company's stock after selling 308,265 shares during the period. Baillie Gifford & Co. owned 3.84% of DexCom worth $1,006,784,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in shares of DexCom in the first quarter valued at approximately $853,000. Empowered Funds LLC boosted its position in shares of DexCom by 30.7% during the 1st quarter. Empowered Funds LLC now owns 5,518 shares of the medical device company's stock valued at $765,000 after acquiring an additional 1,295 shares in the last quarter. QRG Capital Management Inc. boosted its position in shares of DexCom by 10.6% during the 1st quarter. QRG Capital Management Inc. now owns 10,896 shares of the medical device company's stock valued at $1,511,000 after acquiring an additional 1,046 shares in the last quarter. Qsemble Capital Management LP bought a new position in DexCom during the 1st quarter valued at about $627,000. Finally, Avantax Advisory Services Inc. raised its stake in shares of DexCom by 35.4% in the first quarter. Avantax Advisory Services Inc. now owns 3,601 shares of the medical device company's stock worth $499,000 after acquiring an additional 942 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

DXCM traded up $1.65 during trading on Tuesday, hitting $71.96. 1,100,555 shares of the stock were exchanged, compared to its average volume of 3,897,361. The stock has a fifty day moving average price of $69.68 and a two-hundred day moving average price of $92.63. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The firm has a market capitalization of $28.11 billion, a P/E ratio of 42.10, a PEG ratio of 2.15 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Analysts Set New Price Targets

DXCM has been the topic of several analyst reports. Baird R W lowered shares of DexCom from a "strong-buy" rating to a "hold" rating in a report on Friday, July 26th. Morgan Stanley cut their price target on shares of DexCom from $120.00 to $75.00 and set an "equal weight" rating for the company in a research note on Friday, July 26th. Sanford C. Bernstein raised their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Oppenheimer dropped their price objective on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Finally, StockNews.com lowered shares of DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $104.59.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.